2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

More info about license types

Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: 71
Format: PDF
Product Code: LMCA0187
Release Date: March of 2023

La Merie Publishing released on March 07, 2023 the 17th edition of the report series about sales of Blockbuster Biologics. This report provides a compilation of the sales data of originator recombinant therapeutic proteins and antibodies in the calendar year 2022. Sales data were obtained from company publications and refer to branded products. All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of February 01, 2021. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases as constant exchange rates).

Publicly available 2022 sales data of biosimilar antibodies and proteins are included in the report provided from the companies. This report also includes sales data of new biologic modalities such as gene and cell therapy and RNA (antisense, siRNA).

Due to biosimilar erosion of sales of established therapeutic proteins such as erythropoietins, interferon, G-CSF, human growth hormone and FSH, these products are summarized in a new group of established therapeutic proteins.

Sales and growth rates of cancer antibodies were analyzed by subgroup, especially for the strongly growing class of PD-1 & PD-L1 antibodies.

Development of sales of the growing drug modality of antibody-drug conjugates are also presented.

A total of 71 biologic therapeutics reached blockbuster status with 2022 sales exceeding US$ 1 bln. For the first time, sales of 22 new antibody and protein products for the year 2022 were included. Antibody sales represented more than 80% of total biologics sales in 2022. In addition, commercial information about sales of selected biosimilars of recombinant antibodies and proteins is provided.

Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2022 sales higher than US$ 1 bln. Another ranking list was prepared for the TOP 30 companies according to biologics sales in 2022.

Newly included innovator biologics for which sales are reported for the first time are

  • Aidexi
  • Anniko
  • Cejemly
  • Daxxify
  • Elahere
  • Enjaymo
  • Enweida
  • Hansizhuang
  • Idefirix
  • Inmazeb
  • Kimmtrak
  • Lunsumio
  • Opdualag
  • Rolvedon
  • Saphnelo
  • Skytrofa
  • Susvimo
  • Telitacicept
  • Tezspire
  • Vabysmo
  • Vyvgart
  • Xenpozyme

Table of Contents

Currency Exchange Rates

Biologics Sales per Class of Branded Originator Products

In addition:

  • Sales of Established Therapeutic Proteins 2012 – 2022
  • Sales and Growth Rates of Cancer Antibodies by Subgroup 2012 – 2022
  • Sales and Growth Rates of Other Anti-Inflammatory Antibodies by Therapeutic Area 2012 – 2022
  • Sales of Antibody-Drug Conjugates by Product 2012 – 2022
  • Published Biosimilar Sales 2022 by Company
  • Published 2022 Sales of Other Biologics Based on DNA, RNA & Cells

TOP 30 Company Ranking List for Sales of Innovator Biologics 2022

Blockbuster Biologics in 2022 (by generic name)

Biologic Product Sales 2022:

  1. Cancer Antibodies

1.1 PD-1 & PD-L1 Immuno-Oncology Antibodies

1.2 Other Immuno-Oncology Antibodies

1.3. Cancer Antibodies:

1.3.1 Her2

1.3.2 VEGF & VEGF-R

1.3.3 EGF-R

1.3.4 CD20

1.4 Other Cancer Antibodies

  1. Other Anti-Inflammatory Antibodies:

2.1 Dermatology

2.2 Rheumatoid & Autoimmune

2.3 Neuro-Inflammation (multiple sclerosis, myasthenia gravis)

2.4 Pulmonary & Respiratory

2.5 Gastrointestinal

  1. Anti-TNF Antibodies
  2. Cardiometabolic Antibodies
  3. Ophthalmic Antibodies
  4. Insulin and Insulin Analogs
  5. Recombinant Coagulation Factors
  6. Established Therapeutic Proteins:

8.1 Interferon beta (IFN-β)

8.2 Erythropoiesis Stimulating Agent (ESA)

8.3 human Growth Hormone (hGH)

8.4 Granulocyte Colony Stimulating Factor (G-CSF)

8.5 Follicle Stimulating Hormone (FSH)

  1. Anti-Infective Antibodies
  2. Enzyme Replacement Therapy (ERT)
  3. Migraine & Neurodegenerative Disease Antibodies
  4. Other Proteins:

12.1 Cardiometabolic Proteins

12.2 Cancer Proteins

12.3 Various Proteins

  1. Selected Biosimilar Antibodies & Proteins
  2. Selected Other Biologics

14.1 DNA

14.2 Cell Therapy

14.3 RNA

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.


Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01